In the second quarter of 2008, the company recorded a $4.7 million charge for impairment of goodwill. The impairment was a result of the continued significant decline in our market capitalization subsequent to the company's announcement of its decision to end alfimeprase clinical development.
Research and development expenses were $7.6 million for the second quarter of 2008 compared with $11.2 million for the same period in 2007. The decrease in research and development expenses in 2008 was primarily attributable to a decrease in personnel-related expenses as a result of a reduction in headcount.
General and administrative expenses were $3.7 million for the second quarter of 2008, compared with $7.3 million for the second quarter of 2007. The decrease in general and administrative expenses in 2008 was primarily related to a $1.8 million decrease in personnel-related expenses and a 2007 non-cash impairment charge totaling $1.1 million to write off software implementation costs.
Interest income was $0.7 million for the second quarter of 2008, compared with $1.7 million for the same period in 2007.
"This past quarter, we achieved proof-of-concept with our lead
compound, NU172, a short-acting anticoagulant for the potential treatment
of medical or surgical procedures, such as coronary artery bypass graft
(CABG) surgery, percutaneous coronary intervention and kidney dialysis, and
we have already begun to see data from our subsequent Phase 1b trial which
should complete soon," said Dr. Ted W. Love, chairman and chief executive
officer of Nuvelo. "We continue to maintain a strong financial foundation
with close to two years of operating cash on hand, and we anticipate moving
NU172 into a Phase 2 trial in the fourth quarter of 20
|SOURCE Nuvelo, Inc.|
Copyright©2008 PR Newswire.
All rights reserved